{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:28:31Z","timestamp":1748971711699},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,2,24]],"date-time":"2009-02-24T00:00:00Z","timestamp":1235433600000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The major aim of the study was to compare the pharmacokinetic profile of repeated\u2010dose administration of a prolonged\u2010release (PR) formulation of torasemide with that of an immediate\u2010release (IR) dosage. Sixteen volunteers received one daily dose, on four consecutive days, of 10\u2003mg of torasemide\u2010PR or torasemide\u2010IR in a single\u2010blind, two\u2010treatment, two\u2010period, repeated\u2010dose, cross\u2010over, sequence\u2010randomized clinical trial. Blood samples were collected at various time points on day 1 (single\u2010dose) and on day 4 (repeated\u2010dose) and torasemide concentrations were analysed by LC\/MS\/MS. Diuretic effect and urine electrolytes were measured. Urinary urgency was subjectively assessed by visual analogue scales. Safety and tolerability were also determined. Based on logged values, bioequivalence parameters, were: on day 1, <jats:inline-graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"graphic\/FCP_643_mu1.gif\" xlink:title=\"inline image\" \/> ratio\u2003=\u20031.07 (90% CI 1.02\u20131.1), <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> ratio\u2003=\u20030.69 (90% CI 0.67\u20130.73); and on day 4, <jats:inline-graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"graphic\/FCP_643_mu2.gif\" xlink:title=\"inline image\" \/> ratio\u2003=\u20031.02 (90% CI 0.98\u20131.05), <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> ratio\u2003=\u20030.62 (90% CI 0.55\u20130.70). PR had longer <jats:italic>t<\/jats:italic><jats:sub>max<\/jats:sub> than IR and showed significantly lower fluctuations of plasma concentrations. Urine evaluations were similar with both formulations, although PR showed a lower urine volume in the first hours post\u2010administration. Episodes of acute urinary urgency occurred later and were subjectively less intensive with PR. No significant adverse events were reported.<\/jats:p>","DOI":"10.1111\/j.1472-8206.2008.00643.x","type":"journal-article","created":{"date-parts":[[2009,2,25]],"date-time":"2009-02-25T05:13:56Z","timestamp":1235538836000},"page":"115-125","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of repeated\u2010dose pharmacokinetics of prolonged\u2010release and immediate\u2010release torasemide formulations in healthy young volunteers"],"prefix":"10.1111","volume":"23","author":[{"given":"M.J.","family":"Barbanoj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Antonijoan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Gich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Pelagio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gropper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Guglietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,24]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199141010-00008"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549010-00009"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1976.20"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199100413-00003"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199100413-00004"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199834010-00001"},{"key":"e_1_2_7_8_2","volume-title":"Demadex package insert","author":"Boehringer Mannheim Pharmaceuticals","year":"1993"},{"key":"e_1_2_7_9_2","first-page":"164","article-title":"Pharmacokinetics and metabolism of torasemide in man","volume":"38","author":"Neugebauer G.","year":"1988","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_7_10_2","first-page":"382","article-title":"Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect","volume":"20","author":"Lesne M.","year":"1982","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"e_1_2_7_11_2","first-page":"29","volume-title":"Torasemide: clinical pharmacology and therapeutic applications. Progress in pharmacology and clinical pharmacology","author":"Barr W.H.","year":"1990"},{"key":"e_1_2_7_12_2","first-page":"15","volume-title":"Torasemide: clinical pharmacology and therapeutic applications. Progress in pharmacology and clinical pharmacology","author":"Barr W.H.","year":"1990"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.08.024"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/ajhp\/52.16.1771","article-title":"Torsemide: a new loop diuretic","volume":"52","author":"Fowler S.","year":"1995","journal-title":"Am. J. Health Syst. Pharm."},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v16.i6.20"},{"key":"e_1_2_7_16_2","first-page":"187","volume-title":"Pharmaceutical statistics: practical and clinical applications","author":"Bolton S.","year":"1990"},{"key":"e_1_2_7_17_2","unstructured":"American Hospital Formulary Service (AHFS Drug Information\u00ae).American Society of Health\u2010System Pharmacist Inc. Bethesda 2000 pp.2422."},{"key":"e_1_2_7_18_2","volume-title":"Analytical method validation for the measurement of torasemide in human plasma samples by LC\/MS\/MS","author":"Pelagio P.","year":"2004"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_7_20_2","volume-title":"Note for guidance on the investigation of biovailability and bioequivalence","author":"EMEA","year":"2001"},{"key":"e_1_2_7_21_2","first-page":"83","volume-title":"Clinical pharmacokinetics. Concepts and applications","author":"Rowland M.","year":"1995"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005275894"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.116"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00015.x"},{"key":"e_1_2_7_25_2","first-page":"450","article-title":"Response of the kidney to furosemide I. Effects on salt intake and renal compensation","volume":"102","author":"Wilcox C.S.","year":"1983","journal-title":"J. Lab. Clin. Med."},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90069-2"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936050-00005"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1472-8206.2008.00643.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1472-8206.2008.00643.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:43:53Z","timestamp":1697345033000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1472-8206.2008.00643.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1472-8206.2008.00643.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1472-8206.2008.00643.x","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"2009-02-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}